@nudrugdiscovery
Based at Newcastle University, part of Cancer Research Horizons [ https://t.ly/AAaA7 ] & the Newcastle Centre for Cancer. We are an integrated team of medicinal chemists, pharmacologists, cancer & structural biologists developing anticancer therapies
Celebrating #InternationalDayOfWomenAndGirlsInScience and the incredible researches in our Drug Discovery Group who design smarter molecules, who unlock new therapeutic opportunities, and who show every day what is possible when talent is empowered and supported. #WomenInSTEM #CancerDrugDiscovery
Today on #WorldCancerDay we recognise the progress towards better cancer treatments.
At the Newcastle Drug Discovery Group we bring together expertise in cancer biology, structural biology and medicinal chemistry to develop novel therapeutic strategies and more precise targeted therapies.
It's official, our med chem Senior Research Associate @hannahstewart92.bsky.social is the world's fastest scientist @guinnessworldrecords.com guinnessworldrecords.com/world-record...
We're at @durhamuniversity.bsky.social for Day 1 of the @mosmedcdt.bsky.social Conference! Looking forward to two days of insightful talks and discussions - especially from Drug Discovery researchers - highlighting the breadth of ongoing research across the programme.
#mosmed25
Happy International Women's Day!
🌍👩🔬 Celebrating International Women in Science Day! Thank you to all the women in our drug discovery team, their dedication, innovation and inspiration. Together we are pushing boundaries to discover novel anticancer drugs! @nucancer.bsky.social @crhorizons.bsky.social @newcastleuni.bsky.social
Bright field image of cancer cells
Today we celebrate 🌍 #WorldCancerDay 🌎 .
A day to raise awareness and to support affected patients, families and friends.
A day to celebrate our students, researchers and supporters to deliver our ambitious goal to develop novel anticancer drugs. @nucancer.bsky.social @crhorizons.bsky.social
Read about our potential breakthrough in oncology - restoring wild type p53 function with ASTX295. This molecule was co-developed with Astex Pharmaceuticals, and is currently showing great phase I trial readout! #cancer #medchem #clinicaltrials
www.linkedin.com/posts/cancer...
Our research is critically dependent on funding we receive from @cancerresearchuk.org and we are also willing to do our bit towards fundraising. In 2024:
Funds Raised: £6,440 (+£1,031 gift aid)
Online Donations: 283
Events: Great North Run, Race for Life, Shine Walk, Leeds Marathon, bake sale, quiz
Thrilled to share the new collaboration between @diamondlightsource.bsky.social + @crhorizons.bsky.social + @newcastleuni.bsky.social to accelerate structure-based drug development via fragment screening! More here: bit.ly/4g7Et3f 🧬🧶 #chemsky #chembio We're already hard at work on exciting targets 💪
In case you missed it on the other site, we've written up some of our experiences from the CACHE2 hit finding challenge in this blog: cole-group.github.io/2024/09/10/c...
Thanks to the organisers for a well-run challenge!
@creechem.bsky.social @bieniekmat.bsky.social @nataliejtatum.bsky.social
Congratulations to Kenneth Tan who passed his PhD viva on Tuesday 🎉 Kenneth has also recently taken up a position as a Technical Specialist in our structural biology group. Many thanks to his examiners, @nucancer.bsky.social's Luke Gaughan and @universityofleeds.bsky.social's Richard Bayliss!
Looking forward to speaking at the #scireviewmeeting next week. Some interesting topics...
UKRI Future Leaders Fellowship round 10 is opening soon. If you're an early career researcher interested in moving to Newcastle to establish your group, feel free to get in touch!
www.ukri.org/opportunity/...
@utejungwirth.bsky.social and Kleopatra Papa spoke at this week's BACR New Developments in #BreastCancer Research conference, highlighting their work on the effect of chemotherapy on cancer associated fibroblasts and drug resistance 🧫 @nucancer.bsky.social @crhorizons.bsky.social #cancer #cansky
Our multidisciplinary team, with strong industry links, specialises in structural fragment-based approaches for class-leading cancer drug discovery complemented by our strengths in synthetic chemistry, innovative target validation technologies & hit matter finding.
research.ncl.ac.uk/drugdiscovery/
Looking forward to speaking at this on Tuesday. Apparently they are keen to hear about #fraglites and #dels - we will see www.nepic.co.uk/event/nepic-...